Specific Oncolytic Activity of Herpesvirus Saimiri in Pancreatic Cancer Cells

Overview

Journal Br J Cancer

Specialty Oncology

Date 2000 Aug 6

PMID 10917547

Citations 6

Authors

A J Stevenson

M S Giles

K T Hall

D J Goodwin

M A Calderwood

A F Markham

A Whitehouse

Affiliations

Soon will be listed here.

Abstract

The potential use of oncolytic viruses in the treatment of cancer has been investigated for some time. A variety of agents have been studied, including some which appear to be selectively replication-competent in cancer cell lines. In this study, we have investigated the ability of herpesvirus saimiri to specifically lyse selected human cancer cell lines. Upon infection with a replication-competent virus carrying the EGFP reporter gene and a neomycin resistance marker, the pancreatic cancer lines MIAPACA and PANC-1 exhibited definite cytopathic effects. In contrast, the colonic carcinoma cell lines SW480 and HCT116 were phenotypically unaltered. In addition, stable cell lines could not be generated from PANC-1 infected cultures, in marked contrast to cultures of cells from other human tissues. Virus recovery assays demonstrated that all of the cell lines produced a small amount of virus post-infection, but that virus replication was minimal after 1 week in culture. In addition, treatment with acyclovir inhibited virus replication but paradoxically increased cytopathic effect. These data suggest that herpesvirus saimiri may have potential as an oncolytic agent for the treatment of pancreatic cancer.

Citing Articles

Enhancement of Therapeutic Potential of Oncolytic Virus with Homologous Tumor Cell Membranes for Pancreatic Cancer.

Chen W, Liu H, Chen Y, Gao M IET Nanobiotechnol. 2024; 2024:9970665.

PMID: 38863971 PMC: 11095071. DOI: 10.1049/2024/9970665.

Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.

Gujar S, Pol J, Kumar V, Lizarralde-Guerrero M, Konda P, Kroemer G Nat Protoc. 2024; 19(9):2540-2570.

PMID: 38769145 DOI: 10.1038/s41596-024-00985-1.

Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions.

Holbrook M, Goad D, Grdzelishvili V Cancers (Basel). 2021; 13(5).

PMID: 33803211 PMC: 7963195. DOI: 10.3390/cancers13051171.

Genome-wide histone acetylation profiling of Herpesvirus saimiri in human T cells upon induction with a histone deacetylase inhibitor.

Alberter B, Vogel B, Lengenfelder D, Full F, Ensser A J Virol. 2011; 85(11):5456-64.

PMID: 21430050 PMC: 3094983. DOI: 10.1128/JVI.00164-11.

Oncolytic viruses in cancer therapy.

Vaha-Koskela M, Heikkila J, Hinkkanen A Cancer Lett. 2007; 254(2):178-216.

PMID: 17383089 PMC: 7126325. DOI: 10.1016/j.canlet.2007.02.002.

References

Redston M, Caldas C, Seymour A, Hruban R, Da Costa L, Yeo C . p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994; 54(11):3025-33. View

Culver K, Ram Z, Wallbridge S, Ishii H, Oldfield E, Blaese R . In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992; 256(5063):1550-2. DOI: 10.1126/science.1317968. View

Bischoff J, Kirn D, Williams A, Heise C, Horn S, Muna M . An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996; 274(5286):373-6. DOI: 10.1126/science.274.5286.373. View

Roth J, Cristiano R . Gene therapy for cancer: what have we done and where are we going?. J Natl Cancer Inst. 1997; 89(1):21-39. DOI: 10.1093/jnci/89.1.21. View

Sandig V, Brand K, Herwig S, Lukas J, Bartek J, Strauss M . Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med. 1997; 3(3):313-9. DOI: 10.1038/nm0397-313. View

Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff D, Kirn D . ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997; 3(6):639-45. DOI: 10.1038/nm0697-639. View

Arai H, Gordon D, Nabel E, Nabel G . Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A. 1998; 94(25):13862-7. PMC: 28398. DOI: 10.1073/pnas.94.25.13862. View

Rampling R, Cruickshank G, MacLean A, Brown M . Therapeutic replication-competent herpes virus. Nat Med. 1998; 4(2):133. DOI: 10.1038/nm0298-133c. View

Stevenson A, Cooper M, Griffiths J, Gibson P, Whitehouse A, Jones E . Assessment of Herpesvirus saimiri as a potential human gene therapy vector. J Med Virol. 1999; 57(3):269-77. View

10.

Koomey J, Mulder C, Burghoff R, Fleckenstein B, Desrosiers R . Deletion of DNA sequence in a nononcogenic variant of Herpesvirus saimiri. J Virol. 1984; 50(2):662-5. PMC: 255703. DOI: 10.1128/JVI.50.2.662-665.1984. View

11.

Heise C, Williams A, Olesch J, Kirn D . Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther. 1999; 6(6):499-504. DOI: 10.1038/sj.cgt.7700071. View

12.

ELION G . The chemotherapeutic exploitation of virus-specified enzymes. Adv Enzyme Regul. 1980; 18:53-66. DOI: 10.1016/0065-2571(80)90008-4. View

13.

Desrosiers R, Burghoff R, Bakker A, Kamine J . Construction of replication-competent Herpesvirus saimiri deletion mutants. J Virol. 1984; 49(2):343-8. PMC: 255471. DOI: 10.1128/JVI.49.2.343-348.1984. View

14.

Medveczky P, Szomolanyi E, Desrosiers R, Mulder C . Classification of herpesvirus saimiri into three groups based on extreme variation in a DNA region required for oncogenicity. J Virol. 1984; 52(3):938-44. PMC: 254617. DOI: 10.1128/JVI.52.3.938-944.1984. View

15.

Desrosiers R, Bakker A, Kamine J, FALK L, Hunt R, King N . A region of the Herpesvirus saimiri genome required for oncogenicity. Science. 1985; 228(4696):184-7. DOI: 10.1126/science.2983431. View

16.

Desrosiers R, Silva D, Waldron L, Letvin N . Nononcogenic deletion mutants of herpesvirus saimiri are defective for in vitro immortalization. J Virol. 1986; 57(2):701-5. PMC: 252789. DOI: 10.1128/JVI.57.2.701-705.1986. View

17.

Grassmann R, Fleckenstein B . Selectable recombinant herpesvirus saimiri is capable of persisting in a human T-cell line. J Virol. 1989; 63(4):1818-21. PMC: 248459. DOI: 10.1128/JVI.63.4.1818-1821.1989. View

18.

Medveczky M, Szomolanyi E, Hesselton R, DeGrand D, Geck P, Medveczky P . Herpesvirus saimiri strains from three DNA subgroups have different oncogenic potentials in New Zealand white rabbits. J Virol. 1989; 63(9):3601-11. PMC: 250950. DOI: 10.1128/JVI.63.9.3601-3611.1989. View

19.

Nigro J, Baker S, Preisinger A, Jessup J, Hostetter R, Cleary K . Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989; 342(6250):705-8. DOI: 10.1038/342705a0. View

20.

Simmer B, Alt M, Buckreus I, Berthold S, Fleckenstein B, PLATZER E . Persistence of selectable herpesvirus saimiri in various human haematopoietic and epithelial cell lines. J Gen Virol. 1991; 72 ( Pt 8):1953-8. DOI: 10.1099/0022-1317-72-8-1953. View